Hirunrassamee Sanita, Ratanawijitrasin Sauwakon
Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
Int J Health Care Finance Econ. 2009 Jun;9(2):153-68. doi: 10.1007/s10754-009-9062-6. Epub 2009 Apr 26.
Hospitals in Thailand operate in a multiple insurance payment environment. This paper examines (1) access to medicines and other medical technologies, (2) treatment outcomes, and (3) efficiency in resource use, among beneficiaries of the three government health insurance schemes in Thailand. Using 2003-2005 outpatient and inpatient data for patients with three tracer diseases from three government hospitals, we find that utilization of more expensive items differs between patients whose insurers pay on a closed- or open-ended basis. Where new vs. conventional drugs are both available, patients whose insurer pays on a fee-for-service basis tend to have greater access to new drugs, compared to patients whose insurer pays on a capitated or case basis. Similar patterns were found where there are options between originator versus generic drugs, drugs in different dosage forms, and more versus less advanced diagnostic technologies. Effects of insurance payment are more pronounced where price gaps among the medical technologies are significant. Efficiency results are mixed, depending on nature of the disease conditions and type of resources required for treatment.
泰国的医院在多种保险支付环境下运营。本文研究了泰国三项政府医疗保险计划受益人的以下方面:(1)药品和其他医疗技术的可及性;(2)治疗结果;(3)资源使用效率。利用来自三家政府医院的2003 - 2005年三种追踪疾病患者的门诊和住院数据,我们发现,对于保险公司按封闭式或开放式支付的患者,更昂贵项目的使用情况有所不同。在新药和传统药物都有供应的情况下,与保险公司按人头付费或按病例付费的患者相比,按服务收费的保险公司所覆盖的患者往往更容易获得新药。在原研药与仿制药、不同剂型的药物以及先进程度不同的诊断技术之间存在选择时,也发现了类似的模式。当医疗技术之间的价格差距很大时,保险支付的影响更为明显。效率结果喜忧参半,这取决于疾病状况的性质和治疗所需资源的类型。